Skip to contentpdufa.bio

casdatifan ARC-20 (1L and 2L cohorts)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

casdatifan ARC-20 (1L and 2L cohorts) is an Arcus Biosciences, Inc. program in clear cell renal cell carcinoma (ccRCC). Its next catalyst is a Readout in Q4 2027.

RCUS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: clear cell renal cell carcinoma (ccRCC). Sponsor: Arcus Biosciences, Inc. (RCUS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027RCUS

Specialist biotech funds holding RCUS, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors844,816$21.8 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is casdatifan ARC-20 (1L and 2L cohorts)'s next FDA decision or readout?

The next tracked catalyst for casdatifan ARC-20 (1L and 2L cohorts) is a Readout in Q4 2027.

What happened at casdatifan ARC-20 (1L and 2L cohorts)'s most recent FDA decision?

No FDA decision for casdatifan ARC-20 (1L and 2L cohorts) is in our archive yet.

What is casdatifan ARC-20 (1L and 2L cohorts) used for?

In our records casdatifan ARC-20 (1L and 2L cohorts) is under review or in development for clear cell renal cell carcinoma (ccRCC).

Who makes casdatifan ARC-20 (1L and 2L cohorts)?

Arcus Biosciences, Inc. (RCUS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.